Debiopharm International SA Awarded $2.6 Million Grant from CARB-X to Support Development of Debio 1453 to fight drug resistant gonorrhea

Debiopharm, in collaboration with CARB-X, will utilize their state-of-the-art Fabiotics platform to develop novel therapeutics to combat drug-resistant gonorrhea.

July 25, 2017
Debiopharm International

Lausanne, Switzerland – July 25, 2017 – Debiopharm International SA (Debiopharm –, part of Debiopharm Group™, a Swiss-based global biopharmaceutical company, today announced that it has been selected to receive a funding award from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to advance the development of its antibiotic Debio 1453, a FabI inhibitor specifically targeting N. gonorrhoeae.

Press release available here: